Isolation of native human monoclonal autoantibodies to breast cancer.
暂无分享,去创建一个
[1] Yuxian He,et al. Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci1 , 2002, The Journal of Immunology.
[2] N. Cook-Bruns. Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer , 2001, Oncology.
[3] A A Raubitschek,et al. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. , 2001, Journal of immunological methods.
[4] J. Murray. Monoclonal antibody treatment of solid tumors: a coming of age. , 2000, Seminars in oncology.
[5] M. Pfreundschuh. Exploitation of the B cell repertoire for the identification of human tumor antigens , 2000, Cancer Chemotherapy and Pharmacology.
[6] Yao-Tseng Chen. Cancer vaccine: identification of human tumor antigens by SEREX. , 2000, Cancer journal.
[7] N. Takemoto,et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. , 1999, Japanese journal of clinical oncology.
[8] W. Yokoyama. Production of Monoclonal Antibodies , 1999, Current protocols in cell biology.
[9] M. Cronauer,et al. Transforming growth factor‐β in benign and malignant prostate , 1999 .
[10] M. Pfreundschuh,et al. Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. , 1999, Hybridoma.
[11] K. Syrigos,et al. Autoantibodies in the serum of patients with gastric cancer: their prognostic importance. , 1998, Hybridoma.
[12] Yao-Tseng Chen,et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[13] A. Kok,et al. An Enzyme-Linked Immunosorbent Assay for the Measurement of Circulating Antibodies to Polymorphic Epithelial Mucin (MUC1) , 1998, Tumor Biology.
[14] F. Kreutz,et al. Production of highly pure monoclonal antibodies without purification using a hollow fiber bioreactor. , 1997, Hybridoma.
[15] J. Drijfhout,et al. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. , 1997, Cancer letters.
[16] H R Hoogenboom,et al. Designing and optimizing library selection strategies for generating high-affinity antibodies. , 1997, Trends in biotechnology.
[17] S. McDiarmid,et al. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. , 1995, Transplant immunology.
[18] K. Lamborn,et al. Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1 , 1995, The International journal of biological markers.
[19] U. Settmacher,et al. Binding of natural human IgM auto-antibodies to human tumor cell lines and stimulated normal T lymphocytes. , 1994, Immunology letters.
[20] Mahlon D. Johnson,et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. , 1993, The Journal of clinical investigation.
[21] D. Goldenberg,et al. Monoclonal antibodies in cancer detection and therapy. , 1993, The American journal of medicine.
[22] J. Hodgson. Prestidigitation in the Clinic , 1993, Bio/Technology.
[23] D. Czerwinski,et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells , 1992 .
[24] W. Müller‐ruchholtz,et al. New parental cell lines for generating human hybridomas. , 1992, Journal of immunological methods.
[25] L. Presta,et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[26] C. Barbas,et al. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[27] S. Tsuchiya,et al. Human Monoclonal Antibodies against Cytokeratin 18 Generated from Patients with Gastric Cancer , 1989, Japanese journal of cancer research : Gann.
[28] G. Inghirami,et al. Human monoclonals from antigen-specific selection of B lymphocytes and transformation by EBV. , 1986, Science.
[29] I. Royston,et al. UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[30] K. Foon,et al. Determination of the optimal human cell lines for development of human hybridomas. , 1983, Journal of immunology.
[31] R. A. Miller,et al. Tumor therapy with monoclonal antibodies. , 1983, Federation proceedings.
[32] J. Roder,et al. Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[33] C. Davis,et al. Transgenic Mice as a Source of Fully Human Antibodies for the Treatment of Cancer , 2004, Cancer and Metastasis Reviews.
[34] S. Novaković,et al. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients. , 2001, Oncology reports.
[35] V. Leblond,et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] M. Goodall. A simple hollow-fiber bioreactor for the "in-house" production of monoclonal antibodies. , 1998, Methods in molecular biology.
[37] L. Trudel,et al. Evaluation of hollow fiber bioreactors as an alternative to murine ascites production for small scale monoclonal antibody production. , 1996, Journal of immunological methods.
[38] D. Güssow,et al. Humanization of monoclonal antibodies. , 1991, Methods in enzymology.
[39] M. L. Le Beau,et al. Characterization of a novel myeloma cell line, MM.1. , 1989, The Journal of laboratory and clinical medicine.
[40] Khramtsova Sn,et al. Some biochemical mechanisms underlying the impairment of T and B cell immunity in C3HA mice during hepatoma growth. , 1987 .